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Summary 
Interleukin 3 (IL-3) is a hematopoietic stem-cell growth and differentiation factor that is expressed 
solely in activated T and NK cells. Studies to date have identified elements 5' to the IL-3 coding 
sequences that regulate its transcription, but the sequences that confer T cell-specific expression 
remain to be clearly defined. We have now identified DNA sequences that are required for T 
cell-restricted IL-3 gene transcription. A series of transient transfections performed with human 
IL-3-chloremphenicol acetyltransferase  (CAT) reporter plasmids in T  and non-T cells revealed 
that a plasmid containing 319 bp of 5' flanking sequences was active exclusively in T cells. Deletion 
analysis revealed that T cell specificity was conferred by a 49-bp fragment (bp  -319 to  -270) 
that included a potential binding site for AP-1 transcription factors 6 bp upstream of a binding 
site  for Elf-l,  a  member of the  Ets  family of transcription factors.  DNaseI  footprint  and 
electrophoretic mobility shift assay analyses performed with MLA-144 T  cell nuclear extracts 
demonstrated that this 49-bp region contains a nuclear protein binding region that includes consensus 
AP-1 and Elf-1 binding sites. In addition, extracts prepared from purified human T cells contained 
proteins that bound to synthetic oligonucleotides corresponding to the AP-1 and Elf-1 binding 
sites. In vitro-transcribed and -translated Elf-1 protein bound specifically to the Elf-1 site, and 
Elf-1 antisera competed and super shifted nuclear protein complexes present in MLA-144 nuclear 
extracts. Moreover, addition of anti-Jun family antiserum in electrophoretic mobility shift assay 
reactions completely blocked formation of the AP-l-related complexes.  Transient  transfection 
studies in MLA-144 T cells revealed that constructs containing mutations in the AP-1 site almost 
completely abolished CAT activity while mutation of the Elf-1 site or the NF-IL-3 site, a previously 
described nuclear protein binding site (bp  -155 to  -148) in the IL-3 promoter, reduced CAT 
activity to <25%  of the activity given by wild-type constructs. We conclude that expression 
of the human IL-3 gene requires the AP-1 and Elf-1 binding sites; however, unlike other previously 
characterized  cytokine genes such as IL-2, the AP-1 and Elf-1 factors can bind independently 
in the IL-3 gene. Thus, the exact DNA composition of these sites, flanking DNA sequences, 
and the distance between the AP-1 and Ets family binding sites determine the fine specificity 
of nuclear factors that bind to these sites and the resulting inducible, cell-restricted  expression 
of a group of lymphokine genes. 
T 
he growth factor interleukin 3 (IL-3) is a major regu- 
lator of hematopoiesis. The role of IL-3 is particularly 
interesting because IL-3 is secreted from T and NK cells and 
primarily acts on both early stem cells and hematopoietic cells 
committed to distinct lineages (1, 2). Alone, IL-3 stimulates 
the proliferation and differentiation of bone marrow precursor 
cells to produce macrophages, eosinophils, and mast cells, and 
in combination with other growth factors, IL-3 influences 
the development of erythrocytes, megakaryocytes,  and neu- 
trophils (3-5). In addition, IL-3 supports the growth of cell 
lines  derived  from  bone  marrow  cultures  and  enhances 
retrovirus-mediated gene transfer into bone marrow stem cells 
(6, 7). Thus, this lymphokine forms a bridge between the 
immune system and homeostasis in non-immune tissues. 
IL-3 is distinguished from other growth factors by its re- 
stricted cellular expression and mode of induction. Thus, only 
activated CD28 + T cells and NK cells (8-10) produce IL-3, 
whereas growth factors such as GM-CSF and G-CSF are ex- 
pressed in a variety of cell types (11-13). In addition, the agent 
of activation is critical to optimal IL-3 gene induction in human 
T cells. In contrast to other cytokines such as IL-2, TNF-c~, 
lymphotoxin (LT), IFN-%  and GM-CSF, incubation of T 
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the phorbol ester,  PMA, with and without anti-CD28 fails 
to induce substantial IL-3 expression (8, 14). To induce high- 
level IL-3 gene expression, T cells must be activated via the 
TCR/CD3 pathway or with agents that mimic this pathway 
(PMA and ionomycin)  (8). 
Although much is known regarding the biological activi- 
ties and requirements for induction oflL-3 in vitro, relatively 
little is understood about the regulation of expression of this 
gene. The genes for both the murine and the human homo- 
logue of IL-3 have been cloned (15, 16), and comparison be- 
tween the two sequences reveals a low level of sequence iden- 
tity except for some short regions of sequence homology in 
the 5' and 3' flanking regions. Two recent reports have demon- 
strated that  IL-3 mRNA accumulation is controlled at the 
transcriptional  and posttranscriptional  levels  (17,  18).  The 
studies describing transcriptional regulation of the IL-3 gene 
have shown that the IL-3 promoter consists of two activating 
regions separated by an inhibitory region (19-21). The 3' ac- 
tivating region contains two motifs common to many lym- 
phokine promoters,  the CK-1 and CK-2 elements (22).  In 
addition, the 3' activating region contains a sequence similar 
to the Oct-1 motif (23, 24), NF-IL-3,  and an element im- 
mediately 3' that  is similar to a cAMP-responsive element 
(CRE) (25).  These latter two motifs, referred to as ACT-1 
(21) may be important  for IL-3 activation.  The inhibitory 
region includes a sequence referred to as NIP that binds a 
nuclear  protein  in  electrophoretic  mobility  shift  assays 
(EMSA) 1 (19) thought to restrict IL-3 expression to T cells. 
However, as the NIP site also appears to be functionally in- 
hibitory in activated MLA-144 gibbon T cells, this site alone 
cannot be responsible for the restriction of IL-3 expression 
to T  cells. 
A number of recent studies have shown that  the regula- 
tory regions of inducible T cell-related genes contain an AP-1 
nuclear protein binding site in close proximity to an Ets family 
nuclear protooncogene binding  site,  and these sites  are re- 
quired for inducible gene expression (26, 27). Of note, the 
5' activation region of IL-3 contains a consensus binding site 
for the AP-1 transcription factors. Notably, the AP-1 motif 
has  been shown to confer phorbol ester inducibility upon 
heterologous reporter genes (28, 29) and is thought to regu- 
late activation of many inducible genes (30). In addition, the 
human IL-3 promoter contains a consensus Ets family binding 
site 6 bp 3' of the AP-1 motif. Thus, given the distinct lin- 
eage restricted and TCR-inducible pattern of IL-3 gene ex- 
pression, it was of interest to address the molecular mecha- 
nisms underlying  the role of these sites  in regulating  IL-3 
gene expression. 
In this report, we show that the AP-1 and an Ets family 
binding site, Elf-l,  are required for inducible IL-3 gene ex- 
pression. Moreover, the 49obp fragment containing the AP-1 
and Elf-1 nuclear protein binding sites contributes to T cell-re- 
stricted expression of the IL-3 gene.  In contrast  to the re- 
1 Abbreviations used in this paper: CAT, chloramphenicol acetyltransferase; 
EMSA, electrophoretic mobility shift assay. 
quirement  of AP-1  factor  complex  formation  for  NFAT 
binding activity seen in the IL-2 enhancer  (27),  the AP-1 
and Elf-1 sites in the IL-3 gene can bind their respective pro- 
teins or protein complexes independently.  We also confirm 
that  the NF-IL-3 site is required for IL-3 gene expression. 
These data provide the basis for a better understanding  of 
the molecular mechanisms of T cell IL-3 gene regulation and 
its role in the cellular link between the immune system and 
nonimmune  cell  proliferation. 
Materials and Methods 
Cells and Media.  Gibbon lymphosarcoma-infected  T cells, MLA- 
144 (ATCC TIB 201) (American Type Culture Collection,  Rock- 
ville, MD) were cultured in RPMI 1640 medium (Gibco Laborato- 
ries, Grand  Island, NY)  supplemented  with  10%  FCS (Gibco 
Laboratories) and 1% penicillin-streptomycin (Gibco Laboratories). 
RNA I're~ration and Northem Blot A nalysi~  Total  cellular RNA 
was isolated from MLA-144 cells using the guanidinium  isothio- 
cyanate~cesium chloride gradient method (31). RNA samples were 
prepared from cells after incubation with one or more of the fol- 
lowing reagents: PMA (Sigma Chemical Co., St. Louis, MO) alone 
and with ionomycin (Calbiochem Corp., San Diego, CA) or with 
PHA (Sigma Chemical Co.), PMA alone and finally, with media 
only. After equalization by spectrophotometry  and visualization 
in agarose gels containing ethidium bromide, 10 #g of RNA was 
fractionated on a 1% agarose/formaldehyde gel and transferred to 
Hybond-N nylon filters (Amersham Corp.,  Arlington  Heights, 
IL). The filters were hybridized to a human  Ib3 cDNA, which 
was radiolabeled with cz-[3zP]-dCTP by random  hexanucleotide 
priming  (32). 
Isolation of Human  IL3  Genomic Clone and Plasmid Construc- 
tion.  A genomic clone containing  the human  Ib3 gene and 5' 
flanking sequences was isolated from a human  peripheral blood 
genomic library (the generous gift of  John Lowe, Howard Hughes 
Medical Institute,  Ann Arbor, MI) by hybridization  to a human 
II.-3 cDNA probe. Restriction mapping of the Ib3 clone was per- 
formed using  standard techniques (31). 
A set of overlapping DNA sequences from the 5' flanking re- 
gion of the human IL-3 were cloned in 5' to 3' orientation directly 
5' of the bacterial chloramphenicol acetyltransferase (CAT) gene 
in  the promoterless/enhancerless  vector, pCAT-Basic (Promega, 
Madison, WI). 
Transfections.  Various  cell types were transfected with 10-20 #g 
purified supercoiled plasmid DNA prepared by alkaline lysis and 
cesium-chloride  banding  (31). The MLAq44, Clone  13, PEER, 
and Jurkat cells were transfected using the DEAE-dextran method 
as previously described (33). HeLa cells were transfected using 25 
/~g of Lipofectin (Gibco Laboratories). 2/~g of either pRSVBGAL 
or pRSVluciferase DNA was included in each transfection to cor- 
rect for differences in transfection efficiencies  between samples as 
previously described (33). 
CAT, ~-Galactosidas~ and Luciferase Assays.  CeUs  were harvested 
48 h after transfection by four cycles  of freeze-thaw lysis, and pro- 
tein levels were determined using a protein assay (Bio-Rad Labora- 
tories Inc., Richmond, CA). The B-galactosidase and CAT activi- 
ties were determined as previously described (33). Luciferase assays 
were performed essentially as described by De Wet (34) using lu- 
ciferin substrate (Sigma Chemical Co.) and a Pharmacia luminom- 
eter (Pharmacia LKB Biotechnology  Inc., Piscataway, NJ). 
DNA Sequencing.  DNA sequence analysis was performed on 
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termination protocol (35). 
DNase I Footprint Analysis.  A 193-bp subfragment (bp  -319 
to  -126; sense stand) of the flanking II,3 gene was end labeled 
with [c~-32p]-dGTP and [c~-32p]-TTP with the large fragment of 
DNA polymerase 1 (Klenow) and isolated by PAGE. The labded 
193-bp fragment was subjected to partial DNase I digestion as pre- 
viously described (33), after incubation with 100-200/~g of MLA- 
144 nuclear protein extracts. Maxam and Gilbert purine sequencing 
reactions (33) were prepared and electrophoresed in parallel to the 
DNase I digested subfragments. 
EMSAs.  Complementary  oligonucleotides  corresponding  to the 
AP-1, Elf-l, NF-IL-3, and AP-1/Elf-1 nuclear protein binding sites 
were synthesized with overhanging BamHI/BgllI ends and were 
end labeled using Klenow as described above before EMSA: 
AP-1/Elf-I: GATCTGAGCTGAGTCAGGCTTCCCCTTCCTGC- 
CACAGGG 
A~I:GGGCAGGAGGCCTCAGTGAGGTCTCGAGCGCTTCC- 
CCTTCCTGCCACAGGG 
EI~I:  CAGTGAGCTGAGTCAGGCTTCCGAAGGAGACACA- 
GGGGTCCTCTCACCTGCTGC 
All mutations were confirmed  by DNA sequence  analysis.  The AP-1 
nuclear protein binding site was changed from the wild-type se- 
quence (TGAGTCAG) to a mutant sequence (TCTCGAGC.). The 
ELF-1 nuclear protein binding site was changed from the wild type 
(GGCAGGAAGC~) to a mutant sequence (TGTCTCCTTCG). 
Wild-type and mutant multimerized plasmids were constructed 
by multimerization of the same AP-1/Elf-1 EMSA oligonucleotide 
and three additional ologonucleotides: 
AP-1/mE1F-I:  GATCTGAGCTGAGTCAGGCTTCCGCAGCAG- 
ACACCAGGG 
MSVLTR:TCGGAGACGGAAGCGCGC 
Elg1:  GATCTTCCCCTTCCTGCCACAGGG 
NF-Ib3:  GATCCATGGATGAATAATTA 
mA~I/EI~I:  GATCTGAGGTCTCGAGCGCTTCCCCTTCCT- 
GCCACAGGG 
mAFI/mEIgl:GATCTGAGGTCTCGAGCGCTTCCGCAGCAG- 
ACACCAGGG 
A~I:  GATCTGAGCTGAGTCAGGCTTG 
EMSAs were performed as previously described (33) except that 
the binding buffer included 4% Ficoll, 10 mM Tris, 1 mM EDTA, 
1 mM DTT, 75 mM KC1, and 500 ng poly (dI-dC), and the gels 
were run in 0.25  x  Tris-boric acid-EDTA running buffer. Unla- 
beled competitor oligonucleotides (50-200 ng) were included in 
cold competition experiments. EMSAs included either 3-5/~g of 
nuclear extracts prepared from MLA-144 cells (unstimulated and 
stimulated cells), or 3 #1 of in vitro-transcribed/translated protein 
or 1 #g of nuclear extract prepared from unstimulated or stimu- 
lated (10 ng/ml PMA and 400 ng/ml ionomycin for 6-8 h) normal 
human T cells purified  by elutriation (generous  gift of  Drs. Lawrence 
Boise and Craig Thompson, Howard Hughes Medical Institute, 
Chicago, IL). The sequences of oligonucleotide competitors used 
in these studies include the above probes unlabeled and: 
mELF-I: GATCCCTGTGTCTCCTTCGGAA 
MNIP:  GATCCACCTTCTTCACTTGTTCCCA 
Supershift experiments were performed in the presence of 1 #I of 
rabbit or mouse antisera. These antisera were incubated with the 
protein extracts for 15 rain before the addition of DNA probe in 
EMSA reactions. 
Preparation of Mutated Constructs.  Mutations  of the  NF-Ib3 
nuclear protein binding site were introduced by site-directed otigo- 
nucleotide-mediated  gapped-heteroduplex  mutagenesis  as previously 
described (33) using the following synthetic oligonucleotide: 
TGAGTACTAGAAAGTCATGGGACTCGAGGTACGTCTGTGG- 
TTTTCTATGG. 
The wild-type NF-IL-3 site (ATGAATAA)  was changed to a mutaqnt 
sequence (GACTCGAG). (Underlined sequences denote regions 
of mutation.) Mutations were introduced into AP-1 and Elf-1 nu- 
clear protein binding sites using the PCR as previously described 
(33) with the following oligonucleotides: 
These  oligonucleotides were  ligated  in  reverse orientation  to 
pSPCAT, an enhancerless plasmid under the control of the min- 
imal SV40 promoter (36). 
In Vitro Transc@tion/Translation Reactions.  Linearized  cDNAs 
corresponding to  full-length  and  truncated  Elf-1 cDNA  (Elf- 
110s-304; the generous gift of Jeffrey Leiden, University Chicago, 
Chicago, IL) were transcribed using 10 U T7 RNA polymerase, 
40 U RNasin ribonudease inhibitor (Promega) and 0.4 mM rNTPs. 
Transcribed RNAs were then translated in the presence of 0.8 
mCi/ml [sSS]methionine (Amersham Corp.), 40 U  RNasin,  20 
mM amino acids (minus methionine) and 35/~I rabbit reticulocyte 
lysate (Promega). The integrity of translated proteins was assessed 
by SDS-PAGE. 
Antibodies.  Rabbit polyclonal Elf-1 antiserum and preimmune 
rabbit serum (generous gift of  Jeffrey  Leiden), and anti-Jun family 
sera that reacts with all three Jun proteins: JunB, JunE), and c-Jun 
(the generous gift of Rodrigo Bravo, Bristol-Meyers  Squibb Phar- 
maceutical Research Institute, Princeton, NY) were used in some 
EMSA reactions. The Elf-1 antiserum does not react with Ets-1 
or Ets-2. Anti-IL2 receptor (IL-2R; Becton Dickinson, Mountain- 
view, CA) mouse mAb was used in control reactions. 
Results 
Isolation and Characterization of  a Genomic Clone Containing 
the Human 11.-3 Gene.  We isolated a clone containing the 
full-length IL-3 gene from a human genomic library with 
a human IL-3 cDNA as a probe and standard techniques. This 
clone includes 3 kb of 5' flanking sequence  and 5 kb of 3' 
flanking sequence.  To identify regulatory elements in the 5' 
flanking region, we sequenced 1,400 bp of DNA 5' of the 
transcriptional  start site (Fig. 1). A computer homology search 
of the human IL-3 DNA sequence  revealed similarities to 
potential regulatory motifs not previously observed.  These 
include an ets-1  family nuclear protooncogene binding site 
(EBS) with one mismatch (bp - 288 to - 278; antisense strand; 
GGCAGGAAGGG) (37-40), Of note, this EBS contains an 
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AGGCCCAGTTGAAACCAGGGAGTTGCTCTCCTTTCTCCTCCCTTGACCTCACCC~TCAGACCATGCCAATTC 
TGCCTCCTAAACCTCCCAGGCCAGCCCCTCCCCCAGCTCCCAGTGACAGTGTCCTCAGGTACCTGAGCTCAG 
-660  NIP 
CTCTCGGTGCTACCAGAGGGACTGCAGGGCTGCAGAGGCTGAGTCCCACACGCAGGG~C42C.~T~CACT 
GCTAGCAGACCAGTAAGAGAATGGCCACCTGGGGCCTGAGCGCCCTCGGCCATCCACCAGAAACAAAGTGTC 
AAGGAGAAGCTGCCCGAAGCCCATGGGACAAACCACTGGGGACTGGAACACCAGTAATTCTGTATTGGGAAG 
CGGCACCAAGAGATGTGCTTCTCAGAGCCTGAGGCTGAACGTGGATGTTTAGCAGCGTGACCGGCTACCAGA 
CAAACTCTCATCTGTTCCAGTGGCCTCCTGGCCACCCACCAGGACCAAGCAGGGCGGGCAGCAGAGGGCCAG 
-317  AP-I 
GGTAGTCCAGGTGATGGCAGATGAGATCCCACTGGGCAGGAGGCCTCAGTGAGC~k'~G~k~AGGCTTCCCCTT 
Elf-i  -270  NIP  EBS 
~ACAGGGGTCCTCTCACCT~TTCCCATCTCTCATCCTCCTTGACAAGATGAAGTGATA 
NFIL-3  "CRE" 
-i75  (ACT-IB)  (ACT-IA) 
CCGTTTAAGTAATCTTTTTTCTTGTTTCACTGATCTTGAGTACTAGAAAGTCATGCd~TGA~TAATT&C~.TCT 
CK-I/CD28R  CK-2/GATA3  EBS  CACC  Spl 
GTGGTTTTCTAT~GATCCTTCCGACGCCTGCCCCACACCACCACCTCCCCCG 
1 
CCTTGCCCC~GGTTGTGGGCACCTTGCTGCTGCACATATAAGGCGGGAGCTGTTGCCAACTCTTCAGAGCCC 
Start ofl 
CACGAAGGACCAGAACAAGACAGAGTGCCTCCTGCCGATCCAAACATGAGCCGCC  Transcription 
l 
Coding sequences 
B. 
A  AA 
AP-I:  TGACTCA  EBS:  AGGAGGATGTG 
G  GACC  CAA 
TRE:  TGAGTCAG  -277:  5'  GGCAGGAAG~G  3' 
-301:  5'  TGAGTCAG  3' 
Figure  1.  DNA sequence analysis  of the upstream region of the human 
IL-3 gene. The nudeotide sequence of the I1,3 gene from  -855 to the 
start of coding sequences is depicted. Sequences similar to known nuclear 
protein binding sites and those defined in the I1,3 gene are underlined 
and identified. The consensus sequences  for the AP-1 and ets family binding 
sites (EBS), and comparison to sequences in the 11,3 gene are shown in 
B. The single divergent base is underlined. These sequence data are avail- 
able from EMBL/GenBank/DDBJ under accession number L10616. 
A at nucleotide 8, which has been shown to permit binding 
to the Elf-1 transcription  factor (41).  Two additional  EBS 
are present in the IL-3 5' flanking sequences (-108 to  -98; 
-230 to  -220), in addition to a CD28-responsive element 
(CD28R; bp  -126 to  -116; GAGGTTCCATG) (42). The 
finding of a CD28-responsive element is of interest because 
earlier studies in this laboratory demonstrated that IL-3 gene 
expression is limited to the CD28 + T cell subpopulation (8). 
Contained within the lymphokine CK-2 motif is a consensus 
sequence for the GATA-3 transcription factor (AGATAA) (43), 
and this site is conserved within murine IL-3 gene sequences. 
Finally,  a site similar in 8 of 10 bp to the NIP inhibitory 
motif (19) is located 657 bp upstream of the transcriptional 
start  site. 
Identification of  cis-Actin  g Transc@tional  Regulatory Sequences 
that May Be Involved in T Cell-Restricted IL-3 Gene Expres- 
sion.  In an effort to define transcriptional regulatory elements 
that  modulate  IL-3 gene expression,  we examined  a series 
of heterologous reporter constructs containing the bacterial 
CAT gene and human  genomic IL-3 subfragments in var- 
ious cell lines.  Initially, a set of contiguous DNA segments 
from the 5' flanking region of the IL-3 gene was cloned in 
5' to 3' orientation directly 5' of the CAT gene in the promoter- 
less/enhancerless  vector, pCAT-basic.  As shown in Fig. 2, con- 
structs containing 150 bp (which includes the CK-1, CK-2, 
and CRE elements) and 175 bp (which includes the CK-1, 
-319  -270  -175  -150 
Cell LJne  Activation  -150CAT  -175CAT  -270CAT  -319CAT 
8s0.5  4,0.6  1,0.4  4,1 
Jurkat 
+  128,2  88,14  2,0.7  37,10 
PEER  1  1  1  1 
+  21, 2  65,27  1  119,39 
MLA-144  5,0.8  12,8  1,0.5  10,4 
+  86,32  115,41  3,1  158,62 
Clone 13  8,0.3  3  1  2, 0.7 
+  18,3  16,4  1  2,0.3 
HeLa  25,1  13, 4  1  1 
Figure 2.  Transcriptional  activity of CAT  constructs  containing 5' 
flanking region DNA segments of the human I1,3 gene in various cell 
lines. II.~3-CAT  constructs  containing 150-319 bp of 5' flanking DNA 
sequences of the human Ib3 gene with 30 bp of 5' untranslated DNA 
cloned into pCAT were transiently transfected into Jurkat,  PEER,  and 
MLA-144 T cells, into Clone 13 B cells, and into HeLa fibroblasts, along 
with an efficiency  plasmid, pRSV3gal or pRSVluciferase, and tested for 
transcriptional activity. Some of the nuclear protein binding  sites that these 
constructs  included are shown at top.  Following transfection,  the cells 
were divided into two groups: the first was maintained in media only  while 
the second was induced with activation agents known to elicit 11,3. The 
activation agents (denoted by +) used in Jurkat, PEER,  and Clone 13 
cells were PMA (5 ng/ml) and ionomycin (400 ng/ml), and those used 
in MLA-144 cells were PHA (2/zg/ml) and PMA (5 ng/ml). The various 
cell lines were induced for 6-8 h before the harvest of extracts, and these 
extracts, normalized for transfection efficiencies,  were used in CAT assays 
as previously described. Relative CAT activity is shown in the table (mean 
and SD) and represents the activity given by a particular construct com- 
pared to the activity given by the pCAT vector alone. Each construct was 
tested four times in  Jurkat, PEER, and MLA-144  cells, three times in Clone 
13 cells and twice in HeLa cells with different plasmid preparations. 
CK-2, CRE, and NF-II.-3 elements) of 5' flanking sequence 
(with 30 bp of 5' untranslated sequences) increased CAT ac- 
tivity after activation in all cell lines tested. CAT activity was 
also observed in transfected HeLa cells and lower level  ac- 
tivity was demonstrated in unstimulated  T  and B cells.  In 
contrast, a construct containing 319 bp of 5' flanking sequence 
was active exclusively in T  cells.  Deletion analysis  demon- 
strated that this activity was lost in T cells when 49 bp was 
removed from the 319-bp construct,  and this construct was 
also inactive in non-T cell lines.  The 49-bp DNA segment 
(bp  -319 to  -270) contains a consensus AP-1 nuclear pro- 
tein binding  site  (bp  -301  to  -295)  6 bp 5' to the Elf-1 
nuclear protein binding  site described above.  Such an AP- 
1/Ets family member nuclear protein binding cassette has been 
implicated in the activation of other cytokine genes (26, 27). 
Although  -270CAT included the putative silencer NIP, 
mutation of the NIP site from GCTC~CATGC to TCTTCA- 
CTTG in the context of -270CAT failed to increase CAT 
activity in MLA-144 T  cells or in Clone 13 B ceils to the 
level demonstrated by -  175CAT (data not shown). This sug- 
gests that additional DNA sequence is necessary for full ac- 
tivity in T cells regardless of the status of NIP site integrity, 
or that the low-level activity given by  -270CAT is not en- 
1684  Molecular Regulation of the Human Ib3 Gene tirely due to the NIP site.  Together,  these data provide evi- 
dence that the 49-bp fragment is required for the T  cell-re- 
stricted  pattern  of IL-3  gene  expression  and  that  it  may 
function in concert with other negative regulatory elements 
within  the  IL-3 promoter. 
Activation of MLA-144  Cells Induces High-level IL-3 Gene 
Transcripts and Nuclear Proteins that Bind to DNA  Sequences 
within the 49-bp Fragment in the 5' Flanking  Sequences of the 
IL-3 Gene.  To study further the role of the 49-bp fragment 
in IL-3 gene transcription,  it was necessary to identify cells 
that could be induced to express high levels of IL-3. Northern 
blot analysis of tLNA obtained from Jurkat and PEER T cells 
revealed that these cells produced extremely low levels of IL-3 
gene transcripts (data not shown). However, as shown in Fig. 
3 A,  MLA-144 cells can be induced by incubation for 8 h 
with PMA (5 ng/ml)  and PHA (2/~g/ml)  to produce high 
levels of IL-3 gene transcripts and to a lesser degree after in- 
cubation with PMA (5 ng/ml)  and ionomycin (400 ng/ml) 
or with PMA (100 ng/ml) alone. These levels were comparable 
with levels  of IL-3 expression obtained in primary  human 
T cells (L. Gottschalk, unpublished results). Notably, no IL-3 
gene transcription was detected in R.NA prepared from cells 
incubated with  media  alone. 
These data confirm that,  unlike other inducible cytokine 
genes, IL-3 gene expression is not induced with PHA alone 
(8) and suggest that relatively unique molecular mechanisms 
may regulate IL-3 gene transcription.  To identify nuclear pro- 
tein binding sites within the 49-bp subfragment of the human 
IL-3 gene promoter that conferred T  cell specificity in CAT 
assay studies, we subjected a 193-bp DNA subfragment (bp 
-319 to  -126;  sense strand) containing the 49-bp segment 
(bp  -319 to  -270) to DNaseI footprint analysis.  Fig. 3, B 
and C  shows that nuclear extracts prepared from MLA-144 
cells protected the AP-1 site, Elf-1 site, and intervening DNA 
from digestion by DNaseI (bracketed and boxed) and that 
no other regions in the 49-bp segment  within  the  193-bp 
fragment  bound nuclear proteins.  Because these sites  were 
protected by nuclear extracts prepared from both unstimu- 
lated and stimulated MLA-144 cells, further characterization 
of the proteins  that interact with the IL-3 gene DNA was 
performed by EMSAs. 
MLA-144 Cells Contain Multiple Specific  Nuclear Proteins that 
Bind to DNA  Sequences in the IL-3 Promoter.  To determine 
the number and the specificity of nuclear proteins that bind 
to the protected sequences present  in  the 49-bp  IL-3 gene 
subfragment,  we performed a series  of EMSAs with MLA- 
144 nuclear extracts and double-stranded synthetic oligonu- 
cleotides corresponding  to the AP-1 and Elf-1 nuclear pro- 
tein binding sites. Fig. 4 A  shows that when nuclear extracts 
from resting MLA-144 cells were tested with the AP-1/EIf- 
1  DNA  probe  (including  intervening  DNA),  four  low- 
mobility bands (arrows) bound specifically,  as demonstrated 
by competition with wild-type oligonucleotides (lane 2) but 
not by unrelated DNA competitor (MNIP, lane 6) or a mu- 
tant Elf-1 DNA competitor (lane 4). Specific bands were also 
demonstrated using stimulated MLA-144 extracts; however, 
with the exception of the lowest mobility band,  the bands 
were diffacult  to distinguish.  Of note,  the highest mobility 
bands do not appear to be specific because they are present 
despite the addition of wild-type DNA competitors. Further 
cold competition experiments revealed that an oligonucleo- 
tide corresponding to a consensus AP-1 nuclear protein binding 
site competed the middle complexes in both unstimulated 
and stimulated nuclear extracts (lanes 5 and II).  In contrast, 
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Figure 3.  Northern  blot analysis of MLA-144 RNA 
and DNase I footprint analysis  of the 5' flanking region 
of the human Ib3 gene. (.4) Northern blot analysis of 
human II.,3 expression in MLA-144  cells during activa- 
tion. Total cellular RNA was prepared from MLA-144 
cells incubated for 8 h with either media alone, or with 
PMA (5 ng/ml) and ionomycin  (400  ng/ml), or with PMA 
(5 ng/ml) and PHA (2/~g/ml), or with PMA (100  ng/ml) 
alone or with PHA (2/zg/ml) alone. Ten/,g of RNA 
from each condition was equalized for  28S and  18S 
ribosomal tLNA, fractionated  by gel dectrophoresis, and 
transferred to nylon. The nylon filter was hybridized to 
a radiolabeled human II.,3 DNA probe and later hybrid- 
ized to a human B-actin DNA probe and the resulting 
autoradiograms are shown. (B) DNase I footprint anal- 
)'sis of the 5' flanking sequences  of the human Ib3 gene. 
A 193-bp  fragment (bp - 319 to - 126; sense  strand) was 
end labeled  and incubated  with unstimuhted (uns) or with 
stimulated (stira) or without (Contro~  MLA-144  nudear 
extract before  partial digestion with DNase I. Standard 
Maxam and Gilbert purine (G + A) sequencing  reactions 
of the same fragment were prepared and run in parallel. 
The protected  DNA segment that includes  AP-1 and Elf-1 
nuclear protein binding sites is marked with brackets in 
B and boxed  within the DNA sequence  in C. The AP-1 
and Elf-1 nuclear protein  binding sites  are underlined in C. Figure  4.  EMSA  analyses  of the AP-1/Elf-1 nuclear protein  binding sites 
in the human I1.-3 gene. (A) EMSA  using a radiolabeled  AP-1/EIf-1  DNA 
probe and nuclear extracts from unstimulated or PMA/PHA-stimulated 
MLA-144  cells  in the presence  of 200 ng of unlabeled  double-stranded  oli- 
gonucleotide competitors as marked. (B) EMSA analyses using radiola- 
beled AP-1 as a probe with stimulated MLA-144  nuclear extracts. Unla- 
beled competitor oligonucleotides (200 ng) were used as marked. 
competition with an oligonucleotide that corresponds to the 
Elf-1 site alone showed that the lowest mobility specific band 
is competed when mixed with the AP-1/EIf-1 probe and both 
stimulated and unstimulated extracts.  In addition,  when an 
Elf-1 DNA competitor is added in EMSA at the same time 
with AP-1 DNA competitor,  the lower predominant  band 
evident in lanes 5 and 11  (AP-1 DNA competitor alone) is 
reduced suggesting that  there are two bands that run with 
similar mobility, one binding to the AP-1 site and one binding 
to the Elfol site (data not shown). Together, the EMSAs dem- 
onstrate  specific  and  distinct  complex formation  with  the 
AP-1/Elf-1 oligonucleotide probe and proteins from both un- 
stimulated  and  stimulated  MLA-144 cells. 
Fig. 4 B shows that  an oligonucleotide corresponding to 
the AP-1 binding site in the IL-3 gene specifically bound nu- 
clear proteins from stimulated MLA-144 cells in the absence 
of the Elf-1  site  (lanes  1, 3,  and 4).  However, comparison 
of the complexes formed with the AP-1/EIf-1 probe described 
above to  those formed with  the AP-1  probe alone  (Fig.  4 
B) and the Elf-1 probe alone (see Fig. 6, lane 5) demonstrate 
that at least some of the binding activity observed with the 
AP-1/Elf-1 probe may require cooperative binding of AP-1 
and Elf-1 or of yet undefined transcription  factors. Of note, 
the addition of unlabeled NF-IL-3 competitor eliminated all 
complex formation observed with a labeled AP-1 consensus 
probe (Fig.  4 B, lane 2) and stimulated extracts, suggesting 
that the NF-IL-3 nuclear protein binding site may bind AP-1 
transcription  factors. 
The AP-1/EIf-1 DNA Probe  Binds In Vitro Transcribed/Trans- 
lated Elf-1 Protein  and ls Competed by Anti-Elf-I Sera.  To test 
whether Elf-1 protein binds to the EBS in the IL-3 promoter, 
truncated and full-length in vitro-transcribed/translated Elf-1 
protein was used in EMSAs with the AP-1/Elf-1 DNA probe. 
Because  truncated  Elf-1  protein  (Elf-ll0s-3o4) binds  with 
equivalent specificity as full-length Elf-1 protein (44) and be- 
cause of higher  translation  efficiency  of smaller  transcripts 
in vitro,  the truncated  version was used in competition ex- 
periments.  As seen  in  Fig.  5,  the AP-1/EIf-1  DNA probe 
bound truncated Elf-1 (t-Elf-l,  lane 2). This binding activity 
was abolished by the addition of unlabeled wild-type Elf-1 
competitor  (lanes  3  and  4)  but  was  still  present  when 
nonspecific DNA competitor was added (lane 5). As expected, 
no binding activity was observed when in vitro translation 
reactions without transcribed RNA was used in EMSAs (lanes 
1 and 6). Finally,  a control probe that contains an Elf-1 nu- 
clear protein binding site from the MSV LTK (MS V) bound 
the in vitro-transcribed  and translated  tell-1  protein  (lane 
7). These EMSA data demonstrate that Elf-1 protein can bind 
directly to DNA  sequences in  the  IL-3  promoter. 
Addition of  Elf-1 and  Jun Antisera Block Complex Formation 
in EMSA Reactions with MLA-144 Nuclear  Extracts.  To iden- 
tify the proteins within MLA-144 nuclear extracts that bind 
to IL-3 promoter DNA sequences, we performed EMSAs as 
above with  anti-Jun  and  anti-Elf-1  antisera.  Fig.  6  shows 
that addition of anti-Jun family serum which recognizes JunB, 
Jun.D,  and c-Jun blocked the formation of the middle com- 
plexes with both unstimulated and stimulated MLA-144 nu- 
clear extracts (compare lanes I  and 8 with 3 and I0). As de- 
scribed above, the same bands were blocked by addition of 
consensus AP-1 DNA competitor. When specific anti-Elf-1 
serum was added into the EMSA reactions,  it was difficult 
to demonstrate the disappearance of a band using the AP-1/ 
Elf-1 DNA probe (lane 2); however, the higher mobility band 
(closed arrow) formation was blocked in EMSA reactions con- 
taining the shorter Elf-1 DNA probe (f-ELF-I; compare lanes 
5  and 6).  This lower band ran with  the  same mobility as 
Figure 5.  EMSA  with either a radiolabeled  AP-1/Elf-1 probe  or MSV 
probe and in vitro-transcribed/translated truncated Elf-1 (t-Elf-l) or trans- 
lation products prepared without KNA (-). Lanes in which unlabeled 
oligonucleotide competitor was added and the amounts used are noted. 
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nucleotide probes  with unstimulated or stimulated  MLA-144  nuclear pro- 
tein extracts in the presence  of  various antisera. Various  antisera, as noted, 
were incubated with the nuclear proteins for 15 min before  the addition 
of the radiolabeled  probe. Lanes I-7 were  run on one gel while lanes 8-II 
were run on a separate  gel. The complex  corresponding to full-length Elf-1 
(f-Elf-I)  is denoted  by a closed  arrow as well as the supershifted  complexes 
(open arrows) evident in lanes 2, 6, and 11. Preimmune sera and anti-IIr 
receptor (c~-Ib2R) were used as controls. 
the band observed in EMSA reactions containing  in vitro- 
translated full-length Elf-1 protein and the AP-1/Elf-1 probe 
(data not shown). In addition,  a faint supershifted complex 
(open arrow) was observed in reactions containing either DNA 
probe with  unstimulated  MLA-144 nuclear  extracts  (lanes 
2  and 6),  and in reactions with  the AP-1/EIf-1  probe and 
stimulated extracts (compare lanes 10 and 11). The addition 
of IL-2R antibody or preimmune  serum  did not  alter the 
binding activities observed with either probe or with either 
nuclear extract  (lanes  1,  4,  5,  7,  and 9).  Interestingly,  the 
specific band with the lowest mobility observed with both 
probes (lanes 2 and 6) was unaffected by addition of the Elf-1 
antiserum.  However,  the  binding  activity  appeared  to  be 
greater in the absence of the AP-1 nuclear protein binding 
site (with Elf-1 probe). This band was also present when nu- 
clear extracts prepared from PEER and Jurkat  T  cells,  and 
Clone 13 B cells were used (data not shown).  In summary, 
these EMSA data demonstrate that MLA-144 T cells contain 
proteins that bind specifically to AP-1 and Elf-1 nucleotide 
sequences,  that  Elf-1 protein binds  to the Elf-1  nucleotide 
sequences in vitro, and that Elf-1 and Jun antisera block pro- 
teins or protein complexes within MLA-144 nuclear extracts 
that  bind to  these two sites. 
Intact AP-1 and Elf1  Nuclear Protein Binding Sites Are Re- 
quired for Full Functional Activity.  We next  asked whether 
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the NF-IL-3, AP-1, and Elf-1 sites  that bound nuclear pro- 
teins played important functional roles in IL-3 gene transcrip- 
tional activation in intact MLA-144 cells. A series of mutant 
IL-3 promoter constructs were produced and tested for tran- 
scriptional activity after transfection into MLA-144 cells. Mu- 
tations were introduced into the  -319-bp promoter in the 
AP-1,  the Elf-l,  the NF-IL-3 nuclear protein binding  sites 
or in a combination of sites (changes noted in Materials and 
Methods and in the figure legend).  In addition,  constructs 
containing multimerized oligonucleotides corresponding to 
the wild-type and mutant  AP-1  and Elf-1  sites with inter- 
vening nucleotides were cloned into a vector under the direc- 
tion of the minimal SV40 promoter and tested for transcrip- 
tional activity. Fig. 7, A  and B shows that the AP-1 and the 
Elf-1 nuclear protein binding sites were necessary for full ac- 
tivity in stimulated MLA-144 cells  both in the context  of 
the endogenous IL-3 promoter (Fig. 7 A) and in constructs 
containing the multimerized DNA segments controlled by 
the minimal  SV40 promoter  (Fig.  7 B).  Finally,  mutation 
of the NF-IL-3 site in  -319CAT reduced CAT activity by 
80%, demonstrating a role for this site as well. Interestingly, 
the reduced CAT activity produced by  -319CAT with the 
NF-IL-3  mutation  in  comparison  to that  produced by the 
wild-type construct  is less dramatic  when  transfected into 
Jurkat T  cells (data not shown). The studies detailed above 
demonstrate the requirement of intact AP-1, Elf-1, and NF  o 
IL-3 nuclear protein binding sites for inducible IL-3 gene ex- 
pression. 
Human  T  Cells Contain Multiple  Inducible Specific Nuclear 
Proteins That Bind to DNA Sequences in the IL-3 Promot~  To 
investigate the interaction of human T  cell nuclear proteins 
with the 49-bp IL-3 promoter sequence, we performed EMSAs 
using various oligonucleotide probes and nuclear extracts pre- 
pared from uninduced and induced, purified human T  cells. 
Before extract preparation,  a portion of the human  T  cells 
was stimulated for 6-8 h with PMA and ionomycin, which 
induces high levels of IL-3 transcripts (data not shown). Fig. 
8 A  shows that  multiple  complexes were formed with in- 
duced T cell extracts and both the AP-1/EIf-1 (lane 2, arrows) 
and the AP-1 DNA probes (lane 4,  arrows). In contrast  to 
EMSA analysis  performed using nuclear  extracts from un- 
stimulated MLA-144 cells,  very little complex formation is 
evident using uninduced human T  cell extracts (lanes  1 and 
3). However, consistent with results obtained with nuclear 
extracts prepared from MLA-144 cells, the band pattern seen 
with human T  cell extracts and the AP-1/Elf-1 probe (lane 
2) compared with the pattern observed with these extracts 
and the AP-1 probe (lane 4) is distinct,  with fewer and less 
intense  complexes formed with  the  AP-1  probe. 
The  specificity of nuclear  protein binding  of induced  T 
cell nuclear  proteins to the AP-1/Elf-1  DNA  subfragment 
was assessed  using unlabeled DNA  competitors,  as shown 
in Fig. 8 B. The two higher mobility bands denoted by dosed 
arrows were specific  as demonstrated by competition  with 
wild-type competitor (lane 2) but not by unrelated compet- 
itor (MNIP, lane 5) or mutated competitor (MEIfl, lane 6). 
Clearly, the lowest mobility band denoted by a dosed arrow 
is nonspecific because it  is  competed by both  specific  and Figure  7.  Functional analysis of three nuclear protein binding sites in 
the human Ib3 gene. MLA-144  cells were transfected with a CAT con- 
struct under the control of 319 bp of the human IL-3  gene promoter (A) 
or with a CAT construct containing three copies of the AP-1/Elf-1 nu- 
clear protein binding sites found in human II:3 under the control of the 
minimal SV40 promoter (B). CAT constructs with mutations in up to 
three of the nuclear protein binding sites were also tested. In addition, 
2/~g of  pKSV/~gal  was included in each transfection to normalize  efficien- 
des. After transfection, the cells were divided into two groups: one that 
received PMA (5 ng/ml) and PHA (2/~g/ml)  8 h before harvest and a 
second group that was incubated with media only. CAT assays were per- 
formed as previously  described (33). (A) Activity of  constructs containing 
mutated nuclear protein binding sites in the context of the endogenous 
II.-3  promoter.  The mutations were (AP-1)  TGAGTCAG  to TCTCGAGC, 
(Elf-l) GGCAGGAAGGG  to TGTCTCCTTCG, and (NF-Ib3) ATGAA- 
TAA to GACTCGAG.  Activity  shown is that of  stimulated MLA-144  cells 
only. Relative CAT activity is that given each construct compared to the 
activity given by the pCAT vector alone. Each construct was transfected 
at least three times and the data shown are from a representative experi- 
ment. (B) Activity of intact and mutant multimerized AP-1/Elf-1  nuclear 
protein binding sites in constructs under the control of the heterologous 
minimal SV40 promoter. The mutations introduced into the AP-1 site 
were identical to A.  The Elf-1 site in  this construct was mutated to 
TGTCTGCTGCC.  Cultures stimulated with PHA/PMA are denoted by 
(+). Relative CAT activity here represents the activity given by the in- 
dividual construct in extracts from induced cultures compared to the ac- 
tivity given by the construct in extracts from uninduced cultures. The 
uninduced and induced samples were assayed on the same day but run 
on two thin layer  chromatographic  plates. Each construct was transfected 
three times with  different preparations of plasmid DNA and the data 
presented are representative of one experiment. 
nonspecific competitors.  The competitions  observed using 
unlabded AP-1 and Elf-1 DNA probes are consistent with 
the pattern seen with MLA-144 nuclear extracts because (a) 
at least one complex is evident in the presence of competitor 
AP-1 oligonudeotide (lane 3, open arrow) and this band runs 
Figure  8.  EMSA  using radiolabeled AP-1/Elf-1  and AP-1 oligonucleo- 
tide probes with nuclear protein extracts prepared from unstimulated and 
stimulated human T cells purified by elutriation. (A) EMSA  using radio- 
labeled AP-1/Elf-1 or AP-1 DNA probes with unstimulated and stimu- 
lated human T cell nuclear extracts. Complexes formed by nuclear pro- 
teins and the AP-1/Elf-1 probe are denoted by dosed arrows, whereas 
complexes formed by nuclear proteins and the AP-1 probe are denoted 
by open arrows. The panels depicting analyses with the AP-1/Elf-1 probe 
and the AP-1  probe represent gels exposed  to film for identical timepoints. 
(B) EMSA  using a radiolabeled AP-1/Elf-1  probe and nuclear extracts from 
stimulated human T cells in the presence of 200 ng of unlabeled double- 
stranded oligonucleotide competitors as marked. 
with similar mobility to the band formed with the same probe 
and in vitro-translated  full-length Elf-1 (lane  7);  and (b) it 
is difficult to demonstrate diminution of the highest mobility 
band denoted by a dosed arrow in the presence of  Elf-1 DNA 
competitor (lane 4), suggesting that there are two bands that 
run with similar mobility. Finally,  the lowest mobility specific 
band observed in EMSA reactions with  the MLA-144 nu- 
clear extracts does not appear to be present in EMSA reac- 
tions  conducted with  human T  cell  nuclear  extracts. 
Discussion 
IL-3 is a potent inducible hematopoietic growth factor that 
is produced solely by activated T  and NK cells.  In this re- 
port, we demonstrated that multiple nuclear protein binding 
sites are required for T cell-restricted expression of the human 
IL-3 gene,  including  sites  that  bind  to AP-1  transcription 
factors and to Elf-l, an Ets family transcription factor. With 
oligonucleotides corresponding to the AP-1 and Elf-1 binding 
sites,  we have shown by direct binding and competition that 
these sites,  in fact, bind AP-1 and Elf-1 transcription factors. 
In the absence of a DNA subfragment containing the AP-1 
and Elf-1 binding sites,  CAT constructs including a segment 
of the IL-3 promoter/enhancer  were active in both T  and 
non-T cells.  In addition,  mutation  of an element  thought 
to be involved in restricting IL-3 expression,  NIP, failed to 
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fragment when transfected into activated T and non-T cells. 
Together, these data support the conclusion that the AP-1/ 
Elf-1 cassette is critical to cell-restricted and inducible IL-3 
gene expression. 
The AP-1 and Elf-1 binding sites were found to be abso- 
lutely required for IL-3 gene expression, because constructs 
with these sites deleted  were inactive  in induced T cells. DNaseI 
footprint and EMSA analyses  revealed  that the AP-1 and Elf-1 
binding sites as well as intervening DNA bound multiple 
specific nuclear protein complexes, and there were differences 
in the mobilities but not the intensities of the complexes ob- 
served in EMSAs using extracts from resting or induced MLA- 
144 cells. These results suggest  that there may be distinct 
nudear proteins  that bind to the IL-3 promoter in induced 
and uninduced extracts, or that one or more of these pro- 
teins might undergo posttranslational  modifications after ac- 
tivation,  or that different protein-protein interactions  may 
exist in resting and induced cells. Further studies with an- 
tisera revealed that both Elf-1 and Jun family binding pro- 
teins individually  formed complexes with the AP-1/Elf-1 
DNA probe. The presence of proteins that were blocked by 
Jun family antiserum in extracts from resting MLA-144 cells 
may be attributed to constitutive expression of Jun and Fos 
family proteins in these cells. Evidence for high constitutive 
expression of  JunD, and low but detectable  expression  of  Jun-B, 
c-Jun, and Fra-1 has been demonstrated in other resting cells 
(45, 46). Alternatively, distinct combinations of  Jun and Fos 
proteins  may bind to the IL-3 gene during different stages 
of activation (47). Because it is evident that protein-protein 
interactions between the various Jun and Fos transcription 
factors mediate the differential effects observed in regulation 
of AP-1 proteins (30), examination of the individual constit- 
uents of the Fos/Jun or Jun/Jun complexes binding to the 
IL-3 gene AP-1 site in uninduced or induced MLA-144 T 
cells will be important to elucidate. Finally, EMSA studies 
using purified human T cells demonstrated that binding ac- 
tivities were largely limited to extracts prepared from induced 
cells. This result is not unexpected,  and the demonstration 
of binding activities in unstimulated MLA-144 cell extracts 
possibly reflects the transformed state of the MLA-144 cells. 
The exact DNA composition of the AP-1 and Ets family 
nuclear protein binding sites, flanking DNA sequences, and 
the  distance  between these  sites may determine the fine 
specificity of nuclear factors that bind to these sites. Members 
of the Ets protooncogene family encode transcription factors 
that  bind  to  purine-rich DNA  sequences present  in  the 
promoters and enhancers of several cellular and viral genes 
(26, 33, 38, 40, 49, 50). The core GGA sequences are abso- 
lutely required  for DNA-protein interaction,  whereas  the 
flanking sequences determine the specificity of  DNA binding 
by the different Ets family members (39). With respect to 
the IL-3 gene, examination of the EBS sequence predicts that 
the IL-3 gene can bind Elf-1 because of a permissive A at 
nucleotide 8 (41). Whether an Ets family transcriptional pro- 
tein actually forms a complex with AP-1 dimers or a third 
protein bridge may depend on the distance separating  the 
two nuclear protein binding sites. For example, Boise et al. 
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(27) have shown that  NFAT complex formation requires 
cooperation between an Ets family factor and AP-1 dimers, 
and the EBS and AP-1 binding sites in the NFAT motif are 
1 bp apart.  Likewise, Wasylyk et al. (26) demonstrate that 
the ets-1 protein interacts with AP-1 dimers to activate tran- 
scription through the PEA3 motif in the polyoma enhancer. 
In the oncogene-responsive domain of the polyoma enhancer, 
the ets-1 and AP-1 sites overlap by several  bases, and analyses 
using chimeric constructs revealed that maximal levels of ac- 
tivity were possible only when these sites were adjacent (48). 
In contrast,  the Elf-1 and AP-1 nuclear protein binding sites 
in the IL-3 gene are separated by six nucleotides,  and the 
resulting spatial orientation may account for the observation 
that these sites can bind to some proteins  or protein com- 
plexes independently. 
Although we have demonstrated the critical importance 
of the AP-1 and Elf-1 sequences to inducible, T cell-restricted 
IL-3 gene expression, both AP-1 and Elf-1 transcription factors 
themselves  are found in non-T cells as well as in T cells. There- 
fore, the manner in which AP-1 and Elf-1 binding proteins 
might confer T cell IL-3 specificity is of extreme interest in- 
cluding several  possibilities. First, T cell-specific  proteins may 
interact with the AP-1 or Elf-1 binding factors  but not directly 
with DNA. Second, there may be yet undefined regulatory 
protein binding sites and binding factors not detected by 
DNaseI and EMSA analyses. Finally, the AP-1 and Elf-1 tran- 
scription factors may undergo posttranslational modification 
in vivo leading to T  cell-restricted gene expression. 
Previous investigators have suggested that two different 
nuclear protein binding sites, the NF-IL-3 and the NIP sites, 
may play roles in T cell-specific IL-3 gene expression. For 
example, Davies et al. (21) implicated the NF-IL-3 site (within 
the ACT-1 motif) in IL-3 expression, yet the effect of a mu- 
tation in this site is only evident in the context of a construct 
truncated just 5' to the NF-IL-3  site. Within a larger con- 
struct (300 bp of 5' flanking DNA), the effect of an ACT-1 
mutation is negligible (21). In contrast, our data show that 
mutation of the NF-IL-3 site within the context of 319 bp 
of 5' flanking sequence dramatically reduces CAT activity as 
compared to that of the native IL-3 promoter. There are sev- 
eral possibilities for this discrepancy. First, the designs of mu- 
tant constructs were different.  We mutated specific bases 
within the NF-IL-3 site, whereas Davies replaced the entire 
NF-IL-3  site and the 3' CRE element with a short DNA 
spacer (15 to 6 bp). Thus, in the latter construct the spatial 
interactions were dramatically altered and the NF-IL-3 site 
mutations were not isolated. In fact, when we tested a con- 
struct truncated immediately 3' of the NF-IL-3 site, -150CAT 
(including the CRE or 3' section of ACT-l), this construct 
gave 50-100%  of the activity given by the larger -175CAT 
construct. Thus, Davies' deletion of the CRE site would be 
expected to impact greatly on transcriptional activity. Second, 
the modes of IL-3 gene induction in the transfected MLA- 
144 cells were different.  We induced IL-3 gene expression 
in MLA-144 cells with PHA and PMA, whereas Davies et 
al. activated these cells with PMA alone. Our Northern blot 
analysis shows that IL-3 transcripts  in MLA-144  cells are 
significantly lower following incubation with PMA in con- trast to the levels shown with PHA/PMA stimulation. There- 
fore, the effects of mutations in the larger construct described 
in the other report (21) may not be evident during low-level 
IL-3 gene transcription. Interestingly, our construct with NF- 
IL-3 site mutations which produced significantly less CAT 
activity compared to wild-type constructs after transfection 
into MLA-144 T  cells,  reduced CAT activity only moder- 
ately when tested in Jurkat T  cells.  However, the data de- 
rived from experiments using Jurkat cells must be carefully 
assessed because these cells produce extremely low levels of 
IL-3. 
Two groups have suggested that this lineage-restricted ex- 
pression is primarily regulated by the NIP element  in the 
IL-3 promoter (19-21).  However, mutation of the NIP se- 
quence in the context of -270CAT failed to increase CAT 
activity to the level observed with  the smaller  -175CAT. 
This implies that another negative regulatory element in ad- 
dition to or instead of NIP may be involved in repressing 
IL-3 gene expression.  Alternatively,  in the absence of upstream 
sequences, NIP mutations are unable to restore CAT activity 
to the levels observed with  -  150CAT and  - 175CAT. In any 
event, our data do not support a major role for the NIP binding 
site in the cell specificity of IL-3 gene expression in cells that 
produce significant  quantities  of IL-3 mRNA. 
Our results are of particular interest in light of recent studies 
on both the molecular basis of T cell anergy and T cell cytokine 
deficiency after bone marrow transplantation.  Schwartz and 
Kong et al. (51, 52) have found that antigen-specific anergic 
T cell clones display profound deficiencies in the binding of 
AP-1 transcription  factors to AP-1 nuclear protein binding 
sites. Similar AP-1 nuclear protein deficiencies could well ex- 
plain the T  cell anergy routinely observed following bone 
marrow transplantation  in which T cells arising after trans- 
plant fail to secrete either IL-3 or GM-CSF in response to 
mitogens (53, 54). Thus, T cell activation via AP-1 and EBS 
nuclear binding proteins may be a major molecular check- 
point in the expression of the developmental program of T 
cells  in diverse clinical  settings. 
In summary, these data indicate that 5' flanking sequences 
containing nonadjacent AP-1 and Elf-1 nuclear protein binding 
sites play a major role in conferring T cell specificity to IL-3 
gene expression. In contrast to the NF-IL-3 and NIP sites, 
the effects  of the AP-1  and Elf-1 binding  sites  in reporter 
constructs with 5' flanking IL-3 gene sequences distinguish 
T  cells from non-T cells and are most evident under condi- 
tions of T cell activation that maximally stimulate IL-3 produc- 
tion per se. Future studies identifying the particular members 
of the Jun family, as well as additional proteins involved in 
activation at the AP-1 and Elf-1 sites will be extremely in- 
terestingly in illuminating the molecular basis of the specificity 
of T  cell cytokine gene expression. 
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